MedTrace Logo

Effects of Colesevelam HCl On Bile Acid Kinetics

NCT00476710 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2015-04-01

No results posted yet for this study

Summary

This project will compare the amount of bile acids and their kinetics in overweight and obese people with normal glucose metabolism, impaired glucose tolerance and frank type 2 diabetes. We hypothesize that bile acids will behave differently in these groups. We will also explore the effects of Colesevelam HCl, a medicine that lowers LDL cholesterol by binding bile acids, on bile acids in those groups. We hypothesize the drug may have different actions on bile acids in subjects with different degrees of abnormal glucose metabolism.

Conditions

Interventions

DRUG

Colesevelam HCl

Sponsors & Collaborators

  • Daiichi Sankyo

    collaborator INDUSTRY

  • University Medical Center Groningen

    collaborator OTHER

  • Diabetes & Glandular Disease Research Associates

    collaborator UNKNOWN

  • KineMed

    lead INDUSTRY

Principal Investigators

  • Elizabeth J Murphy, MD · KineMed, Inc.

  • Folkert Kuipers, PhD · University Medical Center Groningen

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00476710 on ClinicalTrials.gov